Voloridge Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $102M | Buy |
163,963
+148,599
| +967% | +$101M | 0.43% | 46 |
|
|
2026
Q1 | $11.9M | Buy |
+15,364
| New | +$11.8M | 0.05% | 462 |
|
|
2025
Q4 | – | Sell |
-172,836
| Closed | -$97.2M | – | 1325 |
|
|
2025
Q3 | $97.2M | Sell |
172,836
-107,024
| -38% | -$60.5M | 0.33% | 71 |
|
|
2025
Q2 | $147M | Buy |
279,860
+51,590
| +23% | +$28.8M | 0.54% | 25 |
|
|
2025
Q1 | $145M | Buy |
228,270
+16,142
| +8% | +$11.1M | 0.54% | 20 |
|
|
2024
Q4 | $151M | Buy |
+212,128
| New | +$178M | 0.53% | 26 |
|
|
2024
Q1 | – | Sell |
-33,209
| Closed | -$29.2M | – | 1317 |
|
|
2023
Q4 | $29.2M | Buy |
33,209
+600
| +2% | +$494K | 0.11% | 232 |
|
|
2023
Q3 | $26.8M | Buy |
32,609
+14,301
| +78% | +$11.2M | 0.13% | 216 |
|
|
2023
Q2 | $13.2M | Buy |
18,308
+5,464
| +43% | +$4.21M | 0.06% | 391 |
|
|
2023
Q1 | $10.6M | Buy |
12,844
+6,830
| +114% | +$5.15M | 0.05% | 440 |
|
|
2022
Q4 | $4.34M | Buy |
+6,014
| New | +$4.44M | 0.02% | 693 |
|
|
2022
Q1 | – | Sell |
-2,588
| Closed | -$1.63M | – | 1654 |
|
|
2021
Q4 | $1.63M | Sell |
2,588
-21,705
| -89% | -$13.3M | 0.01% | 1136 |
|
|
2021
Q3 | $14.7M | Buy |
24,293
+22,346
| +1,148% | +$13.9M | 0.09% | 295 |
|
|
2021
Q2 | $1.09M | Buy |
+1,947
| New | +$986K | 0.01% | 1221 |
|
|
2021
Q1 | – | Sell |
-43,195
| Closed | -$20.9M | – | 1616 |
|
|
2020
Q4 | $20.9M | Sell |
43,195
-103,466
| -71% | -$55.9M | 0.18% | 133 |
|
|
2020
Q3 | $82.1M | Buy |
146,661
+65,295
| +80% | +$39.6M | 0.68% | 19 |
|
|
2020
Q2 | $50.7M | Buy |
81,366
+72,124
| +780% | +$40.9M | 0.58% | 29 |
|
|
2020
Q1 | $4.51M | Buy |
+9,242
| New | +$3.81M | 0.13% | 178 |
|
|
2019
Q2 | – | Sell |
-8,988
| Closed | -$3.69M | – | 1013 |
|
|
2019
Q1 | $3.69M | Buy |
+8,988
| New | +$3.7M | 0.11% | 183 |
|
|
2018
Q3 | – | Sell |
-57,880
| Closed | -$20M | – | 438 |
|
|
2018
Q2 | $20M | Buy |
+57,880
| New | +$18.1M | 0.54% | 42 |
|
|
2018
Q1 | – | Sell |
-169,460
| Closed | -$63.7M | – | 625 |
|
|
2017
Q4 | $63.7M | Buy |
+169,460
| New | +$68.6M | 1.39% | 12 |
|
|
2017
Q3 | – | Sell |
-72,341
| Closed | -$35.5M | – | 510 |
|
|
2017
Q2 | $35.5M | Buy |
+72,341
| New | +$31.7M | 0.88% | 25 |
|
|
2016
Q2 | – | Sell |
-59,746
| Closed | -$21.5M | – | 383 |
|
|
2016
Q1 | $21.5M | Buy |
+59,746
| New | +$24.6M | 0.5% | 41 |
|
|
2015
Q2 | – | Sell |
-106,231
| Closed | -$48M | – | 373 |
|
|
2015
Q1 | $48M | Buy |
+106,231
| New | +$45M | 2.32% | 7 |
|
Other funds holding REGN
Voloridge Investment Management's REGN Position: Q2 2026 in Review
Voloridge Investment Management increased its Regeneron Pharmaceuticals (REGN) stake by 967% in Q2 2026, buying an estimated $101M and bringing the position to 163,963 shares worth $102M. The position accounts for 0.43% of the portfolio, ranked #46.
Voloridge Investment Management first reported a position in REGN in Q1 2015 and has held it in 24 quarters since. The position peaked at $151M in Q4 2024. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Voloridge Investment Management held 163,963 shares of Regeneron Pharmaceuticals worth $102M as of Q2 2026.
- Voloridge Investment Management bought 148,599 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $101M.
- Regeneron Pharmaceuticals made up 0.43% of Voloridge Investment Management's portfolio in Q2 2026, its #46 holding.
- Voloridge Investment Management first reported a position in Regeneron Pharmaceuticals in Q1 2015 and has held it in 24 quarters since.
- Voloridge Investment Management's Regeneron Pharmaceuticals position peaked at $151M in Q4 2024.
- 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Voloridge Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.